The State of Lung Cancer in Canada: A Comprehensive Overview for Healthcare Professionals

Lung cancer is among the most commonly diagnosed cancers in Canada, and a leading cause of cancer death. Understanding risk factors, obstacles, and emerging treatments can help you better support lung cancer patients in your practice.

Lung Cancer in Canada

Every day, an average of 82 Canadians are diagnosed with lung cancer. Several risk factors increase the risk of developing the condition, and some unique obstacles in Canadian healthcare hinder early detection. 


Lung cancer is the leading cause of death for males and females in Canada and is the most commonly diagnosed cancer. The incidence is higher in males at 61 per 100,000 cases compared to 57.2 per 100,000 in females. 

In 2022, reports estimated that 30,000 Canadians would be diagnosed with lung cancer, representing 13 percent of all new cancer diagnoses. Lung cancer would also cause 24 percent of all cancer-related deaths. 

Risk Factors 

Smoking is the most notable risk factor for lung cancer. About 72 percent of lung cancer cases develop from smoking tobacco, and exposure to second-hand smoke increases the risk for non-smokers by 30 percent

Exposure to asbestos, radon, radiation, and occupational chemicals such as silica dust or welding fumes are also important risk factors. A history of lung cancer, lupus, or lung conditions like tuberculosis and COPD may also increase the risk


One of the biggest obstacles to lung cancer care is a delay in diagnosis and treatment, which leads to worse outcomes and higher mortality. These delays may happen because of challenges in Canadian healthcare, such as:

  • Low lung cancer research funding
  • Lack of full-scale lung cancer screening
  • Care inequity for underrepresented populations
  • Stigma around smoking and nicotine addiction 
  • Complex drug approval process

When Should you suspect Lung Cancer? 

In many instances, symptoms of lung cancer do not appear until the disease is in an advanced stage. As lung cancer progresses, patients might experience:

  • a cough that gets worse or doesn’t go away
  • shortness of breath
  • consistent chest pain that worsens with deep breathing or coughing
  • blood in mucus 
  • wheezing
  • weight loss
  • fatigue
  • hoarseness or other changes to patient’s voice
  • difficulty swallowing
  • swollen lymph nodes in the neck or above the collarbone
  • headache

Patients presenting any of these symptoms should be screened for lung cancer. 

Treatment Options for Lung Cancer in Canada

As with many other types of cancer, local and systemic treatments are standard. While treatment varies depending on the specific type and stage of cancer, patients may benefit from one or more of these lung cancer treatments.

Local Therapy

Surgery is a key treatment for non-small cell lung cancer (NSCLC). Depending on the disease progression, you may need to remove sections of or the entire lung via:

  • Video-assisted thoracic surgery 
  • Robotic-assisted thoracic surgery 
  • Thoracotomy

Endobronchial therapies or radiation may be necessary to treat metastases or to help ease cancer symptoms in palliative stages. Endobronchial therapies remove tumours or kill cancer cells using a bronchoscope and cryotherapy, laser surgery, electrocautery, or brachytherapy.

Systemic Therapy

Systemic therapies affect the entire body and include chemotherapy, immunotherapy, and targeted therapy. These treatments include medications, infusions, and injections such as:

  • Gefitinib or erlotinib — epidermal growth factor receptor protein-tyrosine kinase (EGFR-TK) inhibitors
  • Crizotinib — a ROS1 gene inhibitor often used as a first-line treatment
  • Alectinib, brigatinib, ceritinib — ALK gene inhibitors
  • Atezolizumab, durvalumab, pembrolizumab — PD-1/PD-L1 or immune checkpoint inhibitors

Emerging Therapies

A new drug called nivolumab may improve NSCLC survival rates. In clinical trials, patients received the drug with chemotherapy before surgery. The study found that the combination reduced the risk of recurrence and cancer progression or death by 37 percent compared to chemotherapy alone. It also increased the event-free survival time by almost a year.

Supporting Lung Cancer Patients

Lung cancer has a significant burden on both patients and the Canadian healthcare system. Understanding key risk factors and obstacles can help you understand steps to take in your practice. Learn the current guidelines for detecting lung cancer early with MDBriefCase. 

Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Academy website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Academy website.

Audience and Appropriate Topics

The  Healthcare Leadership Academy welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.


Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Academy may run between 500 and 1000 words. 


MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement